Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development
June 06 2022 - 8:00AM
Business Wire
News Summary:
- New Xevo G3 quadrupole time-of-flight mass spectrometer that is
up to 10X more sensitive than its predecessori for qualitative and
quantitative analyses of challenging molecules.ii
- New CONFIRM Sequence app on waters_connect software platform
designed for nucleic acid sequence confirmation.
- Electrospray ionization (ESI) source couples the Waters’ SELECT
SERIES MRT mass spectrometer to UPLC for characterizing molecules
at fast speeds.
ASMS 2022 – Waters Corporation (NYSE:WAT) today unveiled
new instruments, software and product enhancements to drive drug
discovery and development at the American Society for Mass
Spectrometry (ASMS) 2022 Annual Conference. The products include
the new Xevo™ G3 quadrupole time-of-flight (QTof) mass
spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing
confirmation app for the waters_connect™ software platform and an
electrospray ionization source for the high-resolution Waters™
SELECT SERIES™ Multi-Reflecting Time of Flight (MRT) mass
spectrometer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220606005253/en/
The new Xevo G3 QTof system is a
high-performance, benchtop mass spectrometer for characterizing and
quantifying thermally-fragile molecules in applications such as
biotherapeutics, forensics, metabolite identification, metabolomics
and extractables and leachables. (Photo: Business Wire)
“Innovation in mass spectrometry progresses rapidly. Our product
introductions at this year’s ASMS benefit scientists throughout the
drug development cycle,” said Jon Pratt, Senior Vice President,
Waters Corporation. “For researchers, this means enhanced
capability to answer fundamental scientific questions. For the
analytical scientist compiling analytical data for new drug
filings, it means increased certainty and confidence in knowing
precisely what’s in their samples and in what quantities.”
Waters Xevo G3 QTof – A Laboratory Workhorse
The new Xevo G3 QTof system is a high-performance, benchtop mass
spectrometer for characterizing and quantifying molecules in
applications such as biotherapeutics, forensics, metabolite
identification, metabolomics and extractables and leachables. The
Xevo G3 QTof system is up to 10X more sensitive than its
class-leading predecessor at transmitting thermally fragile
molecules and excels at measuring and characterizing denatured or
native proteins, peptides and other biotherapeutics.
“Biopharmaceutical development and commercialization requires a
deep understanding of product variation, their degradation pathways
and the processes that make them,” said Dr. Andrew Mahan, Associate
Director, Mass Spectrometry Group Leader, Cell Engineering and
Early Development, Janssen. “The extended mass-to-charge ratio
(m/z) range of the Xevo G3 QTof is going to be ideal for the
analysis of multi-specifics and for native MS analyses.”
Waters engineered the Xevo G3 QTof system to reliably give
scientists both reproducible and accurate qualitative and
quantitative information about molecules in their samples whether
in very small or very large amounts.
New Software App for Confirming Nucleic Acid Sequence of
Biotherapeutics
The CONFIRM Sequence app on the waters_connect software platform
helps scientists using a Waters LC-MS System to confirm the nucleic
acid sequence of therapeutics and identify impurities that could
compromise product safety and efficacy.
The CONFIRM Sequence app eliminates 50% of the time it takes for
post-processing data review, accelerating characterization and
development of nucleic acid therapeutics.iii
The new CONFIRM Sequence app is the first sequencing tool to
integrate compliance-ready data acquisition, processing, and
reporting - making it ideal for deployment in regulated development
and Good Manufacturing Practice (GMP) labs.
Coupling UPLC™ to Waters MRT SELECT SERIES Research Mass
Spectrometer with ESI Source for Fast Molecular
Characterization
The Waters SELECT SERIES MRT System is now compatible with
UPLC-MS with an available electrospray ionization (ESI) source.
Coupling the high resolution MRT System with the ESI source enables
scientists to accurately resolve and measure low (<200 ppb)
concentrations of sample analytes at UPLC acquisition speeds for
metabolomics, metabolite identification or peptide mapping
applications.
The superior performance of the SELECT SERIES MRT allows
scientists to get the highest quality mass spectrometry data and
information faster than any commercial mass spectrometer on the
market today, giving scientists a much clearer picture of the
structure of their molecules at the isotope level iv.
Additional Resources
- View Waters ASMS 2022 Online Media Kit for downloadable photos
and content
- Download the Waters Xevo G3 QTof brochure
- Download the poster A New Software Tool for Sequence
Confirmation and Impurity Analysis of Synthetic
Oligonucleotides
- Follow and connect with Waters via LinkedIn, Twitter, and
Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical
instruments and software, has pioneered chromatography, mass
spectrometry, and thermal analysis innovations serving the life,
materials, and food sciences for more than 60 years. With more than
7,800 employees worldwide, Waters operates directly in more than 35
countries, including 14 manufacturing facilities, and with products
available in more than 100 countries.
Waters, Xevo, SELECT SERIES, UPLC and waters_connect are
trademarks of Waters Corporation.
i Vs. the Waters Xevo G2-XS ii For thermally-labile compounds
iii Internal estimate based on 30 minutes to review a single oligo
sequence data set in CONFIRM Sequence compared to 90 minutes with
ThermoFisher’s BioPharma Finder. iv Waters SELECT SERIES MRT mass
resolution >200k FWHM @ m/z 785 and independent of scan time;
highest resolution achieved irrespective of scan rate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220606005253/en/
Brian J. Murphy PR Manager, Corporate Communications Waters
Corporation brian_j_murphy@waters.com +1 508-482-2614
Waters (NYSE:WAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2023 to Apr 2024